These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 12800807)

  • 61. Methods to detect non-compliance and reduce its impact on population PK parameter estimates.
    Gibiansky L; Gibiansky E; Cosson V; Frey N; Stark FS
    J Pharmacokinet Pharmacodyn; 2014 Jun; 41(3):279-89. PubMed ID: 24952228
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
    Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
    Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of Inaccurate Documentation of Sampling and Infusion Time in Model-Informed Precision Dosing.
    Alihodzic D; Broeker A; Baehr M; Kluge S; Langebrake C; Wicha SG
    Front Pharmacol; 2020; 11():172. PubMed ID: 32194411
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.
    Jullion A; Lambert P; Beck B; Vandenhende F
    Pharm Stat; 2009; 8(2):98-112. PubMed ID: 18481279
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN.
    Padullés Caldés A; Colom H; Caldes A; Cerezo G; Torras J; Grinyó JM; Lloberas N
    Ther Drug Monit; 2014 Jun; 36(3):371-7. PubMed ID: 24305626
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
    van Hest RM; van Gelder T; Vulto AG; Mathot RA
    Clin Pharmacokinet; 2005; 44(10):1083-96. PubMed ID: 16176120
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Population pharmacokinetic analysis of pegylated human erythropoietin in rats.
    Jolling K; Ruixo JJ; Hemeryck A; Piotrovskij V; Greway T
    J Pharm Sci; 2004 Dec; 93(12):3027-38. PubMed ID: 15503315
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.
    Ribbing J; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):109-34. PubMed ID: 15379381
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.
    Ette EI; Kelman AW; Howie CA; Whiting B
    Ann Pharmacother; 1993 Sep; 27(9):1034-9. PubMed ID: 8117353
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance.
    Antignac M; Hulot JS; Boleslawski E; Hannoun L; Touitou Y; Farinotti R; Lechat P; Urien S
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):409-16. PubMed ID: 15991041
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Balanced designs in longitudinal population pharmacokinetic studies.
    Ette EI; Sun H; Ludden TM
    J Clin Pharmacol; 1998 May; 38(5):417-23. PubMed ID: 9602953
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A reduction in between subject variability is not mandatory for selecting a new covariate.
    Lagishetty CV; Vajjah P; Duffull SB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Influence of erroneous patient records on population pharmacokinetic modeling and individual bayesian estimation.
    van der Meer AF; Touw DJ; Marcus MA; Neef C; Proost JH
    Ther Drug Monit; 2012 Oct; 34(5):526-34. PubMed ID: 22846895
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.
    Kshirsagar SA; Blaschke TF; Sheiner LB; Krygowski M; Acosta EP; Verotta D
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):35-55. PubMed ID: 17004125
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.
    Bressolle F; Bologna C; Edno L; Bernard JC; Gomeni R; Sany J; Combe B
    Eur J Clin Pharmacol; 1996; 49(4):285-92. PubMed ID: 8857074
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study.
    Choi L; Caffo BS; Kohli U; Pandharipande P; Kurnik D; Ely EW; Stein CM
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):613-36. PubMed ID: 21847635
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data.
    Umpiérrez M; Guevara N; Ibarra M; Fagiolino P; Vázquez M; Maldonado C
    Biomed Res Int; 2021; 2021():3108749. PubMed ID: 33928146
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact.
    Xu XS; Yuan M; Karlsson MO; Dunne A; Nandy P; Vermeulen A
    AAPS J; 2012 Dec; 14(4):927-36. PubMed ID: 22993107
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.
    Jin Y; Pollock BG; Frank E; Florian J; Kirshner M; Fagiolini A; Kupfer DJ; Gastonguay MR; Kepple G; Feng Y; Bies RR
    J Clin Pharmacol; 2009 Feb; 49(2):176-84. PubMed ID: 19179296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.